A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether IMC-A12 offers increased progression-free
survival (PFS) associated with IMC-A12 monotherapy and IMC-A12 in combination with an
antiestrogen therapy in patients with hormone receptor positive advanced or metastatic breast
cancer that have experienced disease progression on antiestrogen therapy.